CD274 and non-small cell lung carcinoma: The use of CGP (TMB>10mutations/Mb) and PD-L1 IHCTPS≥50% in NSCLC identified at least one positive NCCN recommended biomarker for 70.5% (6,661/9,450) of patients in this cohort.